Phuturdex › Diseases › Multiple sclerosis
Drugs in development · updated 30 October 2026
Multiple sclerosis: drugs in development
As of 30 October 2026 there are 94 active clinical trials (recruiting or ongoing, phases I–III) on 93 drugs for multiple sclerosis. 44 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 44 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OcrelizumabOcrevus | III | 12 | NCT06675955 |
| CyclophosphamideCyclophosphamid, Cytoxan | III | 7 | NCT03477500 |
| MethylprednisoloneMethylprednisolon, Methylprenisolone | III | 4 | NCT04544436 |
| Cladribine2-chlorodeoxyadenosine, Mavenclad® | II–III | 3 | NCT04695080 |
| FingolimodGilenya®, Fingolimod Accord® | III | 3 | NCT06408259 |
| OfatumumabKesimpta®, Arzerra® | III | 3 | NCT07189325 |
| RemibrutinibLOU064, Rhapsido® | III | 2 | NCT07225504 |
| RituximabRuxience, Rituxan | III | 2 | NCT07189325 |
| TeriflunomideAubagio®, Teriflunomide Viatris (previously Teriflunomide Mylan)® | III | 2 | NCT06141473 |
| Adderall | II–III | 1 | NCT02676739 |
| AlemtuzumabCampath, Lemtrada® | III | 1 | NCT03477500 |
| CetirizineQuzyttir®, Zerviate® | III | 1 | NCT07472413 |
| CholestyramineQuestran Light®, Questran® | III | 1 | NCT06141473 |
| DiphenhydramineBenadryl, Benadryl Preservative Free® | III | 1 | NCT07472413 |
| Fampridine4-Aminopyridine, Dalfampridine | III | 1 | NCT06136728 |
Sorted by most advanced phase and number of active trials. Showing 15 of 49 drugs.
All 93 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Chronic progressive multiple sclerosis 39 drugs
- Relapsing-remitting multiple sclerosis 26 drugs
- Autoimmune disease of the nervous system 21 drugs
- Neuromyelitis optica 25 drugs
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease 9 drugs
- Stiff-person syndrome 13 drugs
Broader categories
- Immune System Diseases 54 drugs
- Nervous System Diseases 39 drugs
- Demyelinating disease 6 drugs
- Autoimmune disease 94 drugs
- Autoimmune disease of the nervous system 21 drugs
- Neuromuscular disease 14 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009103 “Multiple Sclerosis”.